Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ALEMTUZUMAB1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --21件: 13, 14, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 107, 164, 283, 284, 285, 326 💬
2Alemtuzumab (already received by alemtuzumab cohort between 1991 and 19941件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 46 💬
3Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 46 💬
4Alemtuzumab (Campath )1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 60 💬
5Alemtuzumab (Campath)1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 15 💬
6Alemtuzumab (GZ402673)1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
7Alemtuzumab 0.2 mg1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --2件: 65, 164 💬
8Alemtuzumab 0.3 mg1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --2件: 65, 164 💬
9Alemtuzumab 12 mg1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
10Alemtuzumab 24 mg1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
11Alemtuzumab and Rituximab2件: Alemtuzumab (Alemtuzumab),
Rituximab		2件: Alemtuzumab (Alemtuzumab),
Rituximab 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 60 💬
12Alemtuzumab GZ4026731件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
13Alemtuzumab immunotherapy1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
14Alemtuzumab infusion1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 14 💬
15Alemtuzumab Injection1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
16Alemtuzumab Injection [Lemtrada]1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 13 💬
17Alemtuzumab, Rituximab2件: Alemtuzumab (Alemtuzumab),
Rituximab		2件: Alemtuzumab (Alemtuzumab),
Rituximab 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
18CAMPATH-1H (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab)1件: Alemtuzumab (Alemtuzumab) 💬 --1件: 60 💬
19Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab12件: Acetate,
Alemtuzumab (Alemtuzumab),
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		13件: Cladribine ,
Alemtuzumab (Alemtuzumab),
Rituximab ,
Dimethyl fumarate ,
Fingolimod hydrochloride ,
Glatiramer acetate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod ,
Fingolimod lauryl sulfate 💬 		26件: DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬 		58件: Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 13 💬
20Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq8件: Alemtuzumab (Alemtuzumab),
Cladribine,
Hyaluronidase,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Rituximab,
Ublituximab		10件: Cladribine ,
Alemtuzumab (Alemtuzumab),
Rituximab ,
Hyaluronidase ,
Hyaluronidase ,
Ocrelizumab ,
Hyaluronidase ,
Natalizumab ,
Ofatumumab ,
Ublituximab 💬 		3件: ITGA4,
MS4A1,
RRM1 💬 		21件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
21Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan4件: Alemtuzumab (Alemtuzumab),
Fludarabine,
Melphalan,
Thiotepa		6件: Melphalan ,
Thiotepa ,
Fludarabine phosphate ,
Alemtuzumab (Alemtuzumab),
Fludarabine ,
Melphalan hydrochloride 💬 		1件: RRM1 💬 4件: Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 164 💬